5:14 PM
 | 
Feb 19, 2013
 |  BC Extra  |  Company News

Chiasma grants Roche rights to acromegaly compound

Chiasma Inc. (Jerusalem, Israel) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to develop and commercialize Octreolin octreotide acetate to treat acromegaly and neuroendocrine tumors. Chiasma will receive $65 million up...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >